Octagon Capital Advisors LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Octagon Capital Advisors LP reported 29 stock positions worth $903.6 million. Its top holding was Dianthus Therapeutics (DNTH) at 18.1% of the portfolio, followed by Cogent Biosciences (COGT, 10.0%) and Abivax SA-ADR (ABVX, 8.3%). Compared with Q4 2025, it opened 7 new positions, sold out of 4, added to 7 and reduced 9. The biggest buy was Alumis (ALMS, shares +12%) and the biggest sale Gossamer Bio (GOSS, shares −44%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001839435
- Portfolio Value
- $903.6M (Q1 2026)
- SEC Filing
- 0001839435-26-000003 ↗ filed May 15, 2026
Holdings Value
Holdings 29 stocks · $903.6M
| DNTH Dianthus Therapeutics Inc. | 18.08% | 1,946,667 | $163.4M | Reduce -19.4% |
| COGT Cogent Biosciences Inc. | 10.01% | 2,350,000 | $90.5M | No change |
| ABVX Abivax SA-ADR | 8.34% | 677,000 | $75.4M | Reduce -10.4% |
| ALMS Alumis Inc. | 6.90% | 2,830,700 | $62.4M | Add +11.8% |
| DFTX Definium Therapeutics Inc. | 5.10% | 2,440,000 | $46.1M | Add +9.4% |
| AVBP Arrivent Biopharma Inc. | 5.03% | 1,971,054 | $45.5M | No change |
| TSHA Taysha Gene Therapies Inc. | 4.38% | 8,859,911 | $39.6M | No change |
| KYMR Kymera Therapeutics Inc. | 3.92% | 425,000 | $35.4M | Reduce -20.6% |
| MIRM Mirum Pharmaceuticals Inc. | 3.46% | 338,900 | $31.3M | New |
| BIOA Bioage Labs Inc. | 3.38% | 1,748,000 | $30.6M | Add +9.4% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.30% | 750,000 | $29.8M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 3.23% | 1,450,000 | $29.2M | Add +13.9% |
| XENE Xenon Pharmaceuticals Inc. | 3.15% | 490,000 | $28.5M | New |
| TERN Terns Pharmaceuticals Inc. | 3.09% | 530,000 | $27.9M | New |
| OCUL Ocular Therapeutix Inc. | 2.97% | 3,166,600 | $26.8M | Add +20.7% |
| PALI Palisade Bio Inc. | 1.99% | 10,276,317 | $18.0M | Add +7.4% |
| TRVI Trevi Therapeutics Inc. | 1.96% | 1,485,000 | $17.7M | Reduce -47.3% |
| IRON Disc Medicine Inc. | 1.91% | 270,000 | $17.3M | New |
| AKTS Aktis Oncology Inc. | 1.90% | 960,847 | $17.2M | New |
| CNTX Context Therapeutics Inc. | 1.52% | 5,250,000 | $13.8M | New |
| DTIL Precision Biosciences Inc. | 1.36% | 2,236,732 | $12.3M | Add +16.6% |
| DBVT DBV Technologies SA-Spon ADR | 1.33% | 574,200 | $12.0M | No change |
| UNCY Unicycive Therapeutics Inc. | 0.73% | 1,000,000 | $6.6M | No change |
| BBOT Bridgebio Oncology Therapeut | 0.71% | 719,000 | $6.4M | Reduce -31.1% |
| LXEO Lexeo Therapeutics Inc. | 0.70% | 1,100,000 | $6.3M | Reduce -36.2% |
| PHVS Pharvaris NV | 0.52% | 165,000 | $4.7M | Reduce -75.4% |
| CATX Perspective Therapeutics Inc. | 0.37% | 791,555 | $3.3M | New |
| EVMN Evommune Inc. | 0.36% | 143,472 | $3.3M | Reduce -71.3% |
| GOSS Gossamer Bio Inc. | 0.28% | 7,750,000 | $2.5M | Reduce -44.3% |
Portfolio Sells Q4 2025 → Q1 2026
| GOSS Gossamer Bio Inc. | Reduce -44.3% | 0.28% | −5.12 |
| ABVX Abivax SA-ADR | Reduce -10.4% | 8.34% | −4.42 |
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −2.77 |
| TRVI Trevi Therapeutics Inc. | Reduce -47.3% | 1.96% | −2.45 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −2.43 |
| PHVS Pharvaris NV | Reduce -75.4% | 0.52% | −1.82 |
| LXEO Lexeo Therapeutics Inc. | Reduce -36.2% | 0.70% | −1.45 |
| KYMR Kymera Therapeutics Inc. | Reduce -20.6% | 3.92% | −1.29 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −0.97 |
| BBOT Bridgebio Oncology Therapeut | Reduce -31.1% | 0.71% | −0.92 |
| EVMN Evommune Inc. | Reduce -71.3% | 0.36% | −0.71 |
| PEPG Pepgen Inc. | Sold out | 0.00% | −0.57 |
| DNTH Dianthus Therapeutics Inc. | Reduce -19.4% | 18.08% | +5.61 |
Portfolio Buys Q4 2025 → Q1 2026
| ALMS Alumis Inc. | Add +11.8% | 6.90% | +3.81 |
| MIRM Mirum Pharmaceuticals Inc. | New | 3.46% | +3.46 |
| XENE Xenon Pharmaceuticals Inc. | New | 3.15% | +3.15 |
| TERN Terns Pharmaceuticals Inc. | New | 3.09% | +3.09 |
| IRON Disc Medicine Inc. | New | 1.91% | +1.91 |
| AKTS Aktis Oncology Inc. | New | 1.90% | +1.90 |
| CNTX Context Therapeutics Inc. | New | 1.52% | +1.52 |
| DFTX Definium Therapeutics Inc. | Add +9.4% | 5.10% | +1.37 |
| BIOA Bioage Labs Inc. | Add +9.4% | 3.38% | +0.74 |
| KALV Kalvista Pharmaceuticals Inc. | Add +13.9% | 3.23% | +0.66 |
| CATX Perspective Therapeutics Inc. | New | 0.37% | +0.37 |
| DTIL Precision Biosciences Inc. | Add +16.6% | 1.36% | +0.36 |
| PALI Palisade Bio Inc. | Add +7.4% | 1.99% | −0.82 |
| OCUL Ocular Therapeutix Inc. | Add +20.7% | 2.97% | −1.02 |
Options Activity Q4 2025 → Q1 2026
| CGON CG Oncology Inc. | call | Sold out | 600,000 | $24.9Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.1B | DNTH, DFTX, ABVX, COGT, ALMS |
| Q1 2026 | 29 | $903.6M | DNTH, COGT, ABVX, ALMS, DFTX |
| Q4 2025 | 26 | $798.8M | ABVX, DNTH, COGT, TSHA, GOSS |
| Q3 2025 | 25 | $640.2M | ABVX, DNTH, GOSS, COGT, AVBP |
| Q2 2025 | 29 | $455.3M | DNTH, AVBP, VRNA, TSHA, SPRY |
| Q1 2025Amended | 33 | $460.1M | APLS, DNTH, AVBP, TRVI, CNTA |
| Q4 2024 | 30 | $587.1M | APLS, AVBP, DNTH, CNTA, VRNA |
| Q3 2024 | 40 | $623.9M | APLS, VRNA, GPCR, DNTH, AVBP |
| Q2 2024 | 44 | $606.1M | APLS, DNTH, GPCR, INSM, DYN |
| Q1 2024 | 56 | $822.6M | APLS, ALPN, DNTH, VRNA, DYN |